MX2019008963A - Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico. - Google Patents

Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.

Info

Publication number
MX2019008963A
MX2019008963A MX2019008963A MX2019008963A MX2019008963A MX 2019008963 A MX2019008963 A MX 2019008963A MX 2019008963 A MX2019008963 A MX 2019008963A MX 2019008963 A MX2019008963 A MX 2019008963A MX 2019008963 A MX2019008963 A MX 2019008963A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
visual impairment
ursodeoxycholic acid
composition containing
Prior art date
Application number
MX2019008963A
Other languages
English (en)
Inventor
Ho Song Yeong
Jin Ko Hwi
Original Assignee
Yoos Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoos Biopharm Inc filed Critical Yoos Biopharm Inc
Priority claimed from PCT/KR2018/001770 external-priority patent/WO2018147685A1/ko
Publication of MX2019008963A publication Critical patent/MX2019008963A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Esta descripción se relaciona con una composición para la prevención o el tratamiento de deterioros visuales que comprenden ácido ursodesoxicólico (UDCA). Más particularmente, la descripción se relaciona con una excelente composición farmacéutica para la prevención o el tratamiento de deterioros visuales como por ejemplo degeneración macular, glaucoma o retinopatía diabética la cual se puede formular para una administración oral, una inyección intravítrea o una administración de gotas para los ojos por ácido ursodesoxicólico solubilizado acuoso.
MX2019008963A 2017-02-09 2018-02-09 Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico. MX2019008963A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170018220 2017-02-09
KR1020180015944A KR102252450B1 (ko) 2017-02-09 2018-02-08 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
PCT/KR2018/001770 WO2018147685A1 (ko) 2017-02-09 2018-02-09 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2019008963A true MX2019008963A (es) 2019-09-10

Family

ID=63443030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008963A MX2019008963A (es) 2017-02-09 2018-02-09 Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.

Country Status (12)

Country Link
US (2) US20190255074A1 (es)
EP (1) EP3581185A4 (es)
JP (2) JP6901739B2 (es)
KR (3) KR102252450B1 (es)
CN (1) CN110177556A (es)
AU (3) AU2018218696B2 (es)
BR (1) BR112019009202A2 (es)
CA (1) CA3039500C (es)
GB (1) GB2571644A (es)
MX (1) MX2019008963A (es)
RU (2) RU2723988C1 (es)
SG (1) SG11201906169QA (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR102252450B1 (ko) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
WO2020129964A1 (ja) 2018-12-18 2020-06-25 参天製薬株式会社 ウルソデオキシコール酸を含有する老視の治療または予防剤
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102624174B1 (ko) 2020-09-18 2024-01-23 주식회사 아미코젠파마 수가용화된 담즙산을 포함하는 패혈증, 급성 폐손상 질환, 또는 급성 호흡곤란증후군의 예방 또는 치료용 약학 조성물
CA3210908A1 (en) 2021-02-15 2022-08-18 Santen Pharmaceutical Co., Ltd. Water-based pharmaceutical composition containing ursodeoxycholic acid or salt thereof
CN113151206A (zh) * 2021-04-21 2021-07-23 重庆第二师范学院 一种3α-羟基类固醇脱氢酶、编码基因及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004875A2 (en) * 1998-07-24 2000-02-03 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
KR100848344B1 (ko) * 2000-02-04 2008-07-25 유서홍 담즙산 함유 청정 수용액 제형의 제조
AU2005279961B2 (en) * 2004-08-30 2010-05-13 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
DE602005025391D1 (de) * 2004-11-01 2011-01-27 Seo Hong Yoo Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
CN101048164B (zh) * 2004-11-01 2012-05-09 柳署弘 降低肌萎缩性侧索硬化中神经变性的组合物
JP2008521800A (ja) * 2004-11-24 2008-06-26 セオ ホン ユー 水可溶化胆汁酸投薬処方の乾燥形態、その製造方法及び用途
EP1871385A1 (en) * 2005-02-10 2008-01-02 Regents Of The University Of Minnesota Methods for treating visual disorders
KR20080061327A (ko) * 2006-12-27 2008-07-02 성균관대학교산학협력단 가용성 ｕｄｃａ를 포함하는 직장암 예방 및 치료 조성물
WO2010123156A1 (ja) * 2009-04-23 2010-10-28 国立大学法人鹿児島大学 血管新生抑制剤
US9724357B2 (en) * 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
MX2016009331A (es) 2014-01-23 2016-10-26 Akebia Therapeutics Inc Composiciones y metodos para tratar enfermedades oculares.
CN104083381A (zh) * 2014-07-29 2014-10-08 上海中医药大学 熊去氧胆酸的医药用途
KR102252450B1 (ko) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CA3039500A1 (en) 2018-06-16
AU2018218696B2 (en) 2020-04-09
CN110177556A (zh) 2019-08-27
KR20180092886A (ko) 2018-08-20
AU2021204660A1 (en) 2021-07-29
EP3581185A1 (en) 2019-12-18
KR20220000881A (ko) 2022-01-04
AU2018218696A1 (en) 2019-06-13
US20190255074A1 (en) 2019-08-22
AU2020204384A1 (en) 2020-07-23
KR102252450B1 (ko) 2021-05-14
RU2723988C1 (ru) 2020-06-18
CA3039500C (en) 2021-07-13
SG11201906169QA (en) 2019-08-27
GB201904993D0 (en) 2019-05-22
RU2746592C1 (ru) 2021-04-16
JP2021143192A (ja) 2021-09-24
US20210252022A1 (en) 2021-08-19
JP2019532082A (ja) 2019-11-07
KR102382077B1 (ko) 2022-04-04
JP6901739B2 (ja) 2021-07-14
GB2571644A (en) 2019-09-04
AU2020204384B2 (en) 2021-10-21
KR20190135955A (ko) 2019-12-09
EP3581185A4 (en) 2020-10-28
BR112019009202A2 (pt) 2020-03-03

Similar Documents

Publication Publication Date Title
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
MX361520B (es) Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas.
MX2007008848A (es) Metodos y composiciones para el tratamiento de desordenes oculares.
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MY171920A (en) Prevention and treatment of ocular conditions
WO2007046083A3 (en) Compositions for treatment of eye diseases
WO2017070647A8 (en) Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
WO2011151685A8 (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
BR112022011102A2 (pt) Tratamentos do edema macular diabético e da acuidade visual deficiente
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
WO2011137344A3 (en) Anti-s1p antibody treatment of patients with ocular disease
EP4245295A3 (en) Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
MX2021005077A (es) Peptidos y composiciones farmaceuticas para tratar enfermedades oculares.
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2013001870A (es) Formulaciones oftalmicas de escualamina.
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
BR112017028395A2 (pt) ?polissacarídeo capsular bacteriano, conjugado, e, composição farmacêutica?